Nuvalent (NASDAQ:NUVL) Downgraded by Canaccord Genuity Group to Hold

Nuvalent (NASDAQ:NUVL) was downgraded by equities research analysts at Canaccord Genuity Group from a “strong-buy” rating to a “hold” rating in a research report issued to clients and investors on Tuesday,Zacks.com reports.

A number of other equities analysts have also recently issued reports on the stock. Cantor Fitzgerald cut shares of Nuvalent from an “overweight” rating to a “neutral” rating in a research report on Tuesday. Wedbush cut shares of Nuvalent from an “outperform” rating to a “neutral” rating and cut their price objective for the stock from $125.00 to $124.00 in a research report on Tuesday. Lifesci Capital cut shares of Nuvalent from an “outperform” rating to a “hold” rating and set a $124.00 price objective on the stock. in a research report on Tuesday. Stifel Nicolaus set a $124.00 price objective on shares of Nuvalent in a research report on Tuesday. Finally, Truist Financial set a $124.00 price target on shares of Nuvalent in a research report on Tuesday. Five investment analysts have rated the stock with a Buy rating, fourteen have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Nuvalent currently has a consensus rating of “Hold” and an average price target of $131.15.

Nuvalent Trading Up 0.1%

Shares of Nuvalent stock opened at $123.35 on Tuesday. The business has a 50-day moving average price of $103.44 and a two-hundred day moving average price of $103.19. Nuvalent has a 1-year low of $71.13 and a 1-year high of $123.62. The company has a market cap of $9.74 billion, a P/E ratio of -20.35 and a beta of 1.15.

Nuvalent (NASDAQ:NUVL) last released its quarterly earnings data on Thursday, May 7th. The company reported ($1.39) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.35) by ($0.04). During the same period in the prior year, the company earned ($1.18) EPS. Equities research analysts forecast that Nuvalent will post -5.74 EPS for the current fiscal year.

Insider Activity

In other Nuvalent news, insider Henry E. Pelish sold 3,093 shares of the stock in a transaction dated Thursday, April 9th. The shares were sold at an average price of $104.48, for a total value of $323,156.64. Following the completion of the sale, the insider owned 65,604 shares in the company, valued at approximately $6,854,305.92. This trade represents a 4.50% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Alexandra Balcom sold 11,430 shares of the stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $98.69, for a total transaction of $1,128,026.70. Following the completion of the sale, the chief financial officer owned 85,533 shares of the company’s stock, valued at approximately $8,441,251.77. This trade represents a 11.79% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 126,953 shares of company stock worth $12,612,264. Corporate insiders own 5.02% of the company’s stock.

Institutional Investors Weigh In On Nuvalent

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. GAMMA Investing LLC increased its stake in Nuvalent by 47.6% in the 4th quarter. GAMMA Investing LLC now owns 335 shares of the company’s stock valued at $34,000 after buying an additional 108 shares during the last quarter. EverSource Wealth Advisors LLC increased its stake in Nuvalent by 141.3% in the 1st quarter. EverSource Wealth Advisors LLC now owns 333 shares of the company’s stock valued at $34,000 after buying an additional 195 shares during the last quarter. Aster Capital Management DIFC Ltd purchased a new stake in Nuvalent in the 3rd quarter valued at about $38,000. NBC Securities Inc. purchased a new stake in Nuvalent in the 4th quarter valued at about $125,000. Finally, KBC Group NV increased its stake in shares of Nuvalent by 24.1% during the 4th quarter. KBC Group NV now owns 1,527 shares of the company’s stock worth $154,000 after purchasing an additional 297 shares during the last quarter. Hedge funds and other institutional investors own 97.26% of the company’s stock.

More Nuvalent News

Here are the key news stories impacting Nuvalent this week:

• Positive Sentiment: GSK’s all-cash acquisition offer values Nuvalent at roughly $10.6 billion and implies a meaningful premium to recent trading levels, giving shareholders a clear exit price. Reuters article on GSK deal
• Positive Sentiment: Analysts and market commentary suggest the deal makes strategic sense for GSK because Nuvalent brings a late-stage lung cancer pipeline, reinforcing investor confidence that the transaction is real and financially significant. WSJ article on GSK deal
• Neutral Sentiment: Several law firms have launched investigations into whether the sale process and $124.00 price are fair to shareholders, which could create some headline noise but does not change the announced deal terms yet. Business Wire article on investigation
• Neutral Sentiment: Wells Fargo and other brokers trimmed ratings after the takeover announcement, but their updated price targets remain near the deal value, so these moves are unlikely to outweigh the acquisition news. Analyst downgrade coverage
• Negative Sentiment: CEO James Richard Porter sold 30,000 shares, which may slightly pressure sentiment by reinforcing that insiders have been reducing exposure ahead of the transaction. SEC insider filing

About Nuvalent

Nuvalent, Inc (NASDAQ:NUVL) is a clinical-stage precision oncology company focused on the discovery, development and commercialization of targeted therapies for patients with genetically defined cancers. Founded in 2019 and headquartered in San Diego, California, Nuvalent applies structure-guided drug design to develop small molecule inhibitors that address key oncogenic drivers. The company’s research platform integrates insights from cancer biology, medicinal chemistry and translational science to create therapies with differentiated selectivity and potency against validated targets.

Nuvalent’s lead pipeline candidates include NVL-520, a highly selective RET inhibitor designed to minimize off-target effects, and NVL-655, a potent covalent inhibitor targeting KRAS G12D mutations.